Regencell Bioscience Holdings ($rgc) has gained approximately 223% since its IPO. It went public on the Nasdaq Capital Market on July 16, 2021, in a traditional IPO process.
The company received $21.9 million in gross proceeds from the offering, which is expected to be used to fund the second research study, the company’s TCM formula and products, and general corporate purposes.
On July 20, RGC announced the closing of its public offering at $9.50 per share. The current share price as of 17 July 2022 (a year after its IPO listing) is at $37.30. RGC is a Traditional Chinese Medicine (TCM) biosciences company headquartered in Causeway Bay, Hong Kong. The company conducts research, develops, and commercialises TCM to treat degeneration and neuro-cognitive disorders.
https://pennystocks.com/featured/2021/08/20/rgc-stock-rallying-mistaken-identity-penny-stocks/?amp